Bionano Genomics, Inc. (BNGO) Earnings History
Net Loss10 years of earnings data (2016–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Bionano Genomics, Inc. (BNGO) Earnings Overview
As of June 24, 2026, Bionano Genomics, Inc. (BNGO) reported trailing twelve-month net income of -$32M, reflecting +94.5% year-over-year growth. The company earned $-5.80 per diluted share over the past four quarters, with a net profit margin of -92.6%.
Looking at the long-term picture, BNGO's historical earnings data spans multiple years. The company achieved its highest annual net income of -$18M in fiscal 2018.
Bionano Genomics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including PACB (-$129M net income, -341.5% margin), CDNA (-$8M net income, -5.6% margin), NTRA (-$226M net income, -9.0% margin), BNGO has outperformed on profitability metrics. Compare BNGO vs PACB →
BNGO Earnings vs Peers
Earnings metrics vs comparable public companies
BNGO Historical Earnings Data (2016–2025)
10 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$26M | +76.4% | -$33M | $-4.85 | -92.6% | -116.9% |
| 2024 | -$112M | +51.8% | -$104M | $-88.13 | -364.0% | -337.9% |
| 2023 | -$232M | -75.3% | -$215M | $-408.60 | -643.7% | -596.0% |
| 2022 | -$133M | -83.1% | -$132M | $-267.71 | -476.9% | -473.7% |
| 2021 | -$72M | -76.2% | -$77M | $-157.02 | -402.8% | -428.8% |
| 2020 | -$41M | -37.9% | -$39M | $-14194.80 | -483.4% | -453.4% |
| 2019 | -$30M | -61.2% | -$26M | $-71662.20 | -294.3% | -255.4% |
| 2018 | -$18M | +20.8% | -$20M | $-94089.60 | -154.1% | -170.1% |
| 2017 | -$23M | -24.0% | -$23M | $0.00 | -245.8% | -244.3% |
| 2016 | -$19M | - | -$21M | $0.00 | -277.5% | -311.6% |
Download Data
Export BNGO earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
10+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
BNGO — Frequently Asked Questions
Quick answers to the most common questions about buying BNGO stock.
What is BNGO earnings per share (EPS)?
BNGO trailing twelve-month (TTM) diluted EPS is $-5.80, reflecting +94.5% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2016 to 2025 is available in the table on this page.
What is Bionano Genomics, Inc.'s net income?
Bionano Genomics, Inc. (BNGO) trailing twelve-month net income is $-32M as of 2025. Earnings grew +94.5% year-over-year.
Is BNGO profitable?
BNGO is not currently profitable on a TTM basis, reporting a net loss of $-32M. Net margin is -92.6%. Investors should monitor for a return to profitability.
What is BNGO's earnings growth rate?
BNGO compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2016 to 2025.
What are BNGO's profit margins?
Bionano Genomics, Inc. net profit margin is -92.6%, operating margin is -116.9%, and gross margin is +22.0%. Below-average margins reflect competitive or cost pressures. Return on Equity is -66.2%.
Is BNGO growing earnings?
Yes, BNGO earnings are accelerating — EPS growth of +94.5% exceeds the 5-year CAGR of N/A. TTM net income reached $-32M. Earnings momentum is strengthening.
What was BNGO's best earnings year?
Bionano Genomics, Inc.'s highest annual net income on record is $-18M, achieved in fiscal year 2018. Earnings history on this page spans 2016 to 2025 and includes all annual and quarterly figures.
What were BNGO's earnings last quarter?
BNGO's most recent reported quarter was Q1 2026. Net income was $-8M with diluted EPS of $-0.76. For a full breakdown of all quarters, see the quarterly earnings table on this page.